Bone morphogenic proteins (BMP)
for long bone nonunions and spinal fusions
Coverage decision
L&I covers procedures using bone morphogenic proteins under specific criteria and after undergoing utilization review.
Stryker Biotech's OP-1 Implant is covered as an alternative to autograft in recalcitrant long-bone nonunions where the:
- Use of autograft is unfeasible, and
- Alternative treatments have failed.
Medtronic Sofamer Danek's InFUSE Bone Graft with BMP-2 and LT-CAGE Lumbar Tapered Fusion Device system is covered for single-level anterior lumbar spine fusion in patients with degenerative disc disease at one level from L4-S1.
All claimants undergoing inpatient surgery for fractures or spinal fusions must receive prior authorization.
Bone morphogenic proteins (BMP) are proteins found in the human body that aid in bone modeling, repair and development. To administer BMP locally, BMP is combined with an absorbable collagen sponge made from bovine Type I collagen.
The Food and Drug Administration (FDA) has approved two manufacturers to market BMP for two indications. First, Stryker Biotech's OP-1 Implant is used to treat recalcitrant long bone nonunions. Medtronic Sofamer Danek's InFUSE Bone Graft and LT-CAGE Lumbar Tapered Fusion Device system is used during spinal fusions.
Bone Morphogenic Proteins technology assessments (188 KB PDF)
For more information:
Contact information.
